LNP siRNA THERAPY

Lipid nanoparticle (LNP)-formulated small interfering RNA (siRNA) has recently emerged as efficient and clinically proven approaches in the molecular targeting of disease-driver genes. LNP-formulated siRNA therapy has multiple advantages over traditional therapeutics in cancer therapy (Table 1). For instance, the parenteral administrations of an LNP-encapsulated siRNA specific for transthyretin (TTR) reduce up to 86.8% of transthyretin produced by the liver in patients with hereditary transthyretin-mediated amyloidosis and thus became the first clinically approved siRNA therapy. Antapodia Therapeutics harnesses the third-generation highly biodegradable LNPs in conjunction with a novel "liver-blocking" technology to efficiently deliver invadopodia-targeted siRNA to non-hepatic cancers, resulting in tremendous anti-tumor and anti-metastasis efficacies in preclinical studies. In collaboration with academic and industrial leaders in LNPs, the company strives to develop the best-in-class cancer-gene therapies to concur aggressive and metastatic cancers.

Table 1. Comparison among different anti-cancer therapeutics

 

Specificity

Potential toxicity

Tissue penetration

Intracellular targeting

Duration of effects

Clinically proven

siRNA Very high (1 target transcript)
Very low High Yes 4-7 days 3 FDA approvals1
microRNA Low (>100 target genes)
Medium-to-high High Yes 4-7 days No
Small molecules Medium-to-high Likely High Yes Varied Many
Antibody therapeutics High Low Poor2 -to moderate No 2-3 weeks Many

1ONAPATTRO® (patisiran) for hereditary transthyretin-mediated amyloidosis (approved in 2018); GIVLAARI® (givosiran) for hepatic porphyria (approved in 2019); OXLUMO® (lumasiran) for primary hyperoxaluria (2020).

2Desmoplastic cancers

Logo_vertical_light.png

Designed by Justin V. Tsai in 2021

Copyright © Antapodia Therapeutics, Inc., WA, USA. All Rights Reserved.

Search